1 / 6

T-Cell Immunotherapy Pipeline Analysis - Growth opportunities, Competitive Landscape & Technology

T-Cell Immunotherapy Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights.

NidhiNehani
Download Presentation

T-Cell Immunotherapy Pipeline Analysis - Growth opportunities, Competitive Landscape & Technology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. T-Cell Immunotherapy Pipeline to Witness Huge R&D Investment In The Coming Years

  2. T-Cell Immunotherapy Pipeline Analysis According to a new research report “Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, the T cell immunotherapy exhibits strong pipeline with estimated 139 drug candidates in 2016. T-cell immunotherapy pipeline in 2016 The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates in different stages of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity. Browse the Report Summary at:https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis

  3. T-Cell Immunotherapy Pipeline Analysis Chimeric antigen receptors (CAR) T-cell is majorly researched and developed, representing 75% T-cell immunotherapeutic candidates CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.

  4. T-Cell Immunotherapy Pipeline Analysis Strategic collaborations for the development of T-cell immunotherapeutic The research finds that the different companies are collaborating for the development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and Juno Therapeutics, Inc. collaborated for the development and commercialization of immunotherapies. Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.

  5. T-Cell Immunotherapy Pipeline Analysis Download report sample at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis/report-sample

  6. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related